Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Fresh Frozen Plasma Transfusion Increases Organ Failure in Trauma Patients

By LabMedica International staff writers
Posted on 01 Nov 2010
Transfusion of fresh frozen plasma (FFP) in critically injured patients is associated with an increased risk for multiple organ failure (MOF), according to a new study.

Researchers at the University of Colorado (Denver, USA) conducted a prospective cohort study involving 1,440 critically injured patients admitted to the surgical intensive care unit (ICU) between 1992 and 2004, and survived at least 48 hours. More...
Of these, 1,415 had complete data on age, Injury Severity Score (ISS), and units of FFP, platelets, and packed red blood cells (PRBCs) transfused. The main outcome measure was MOF; multiple logistic regression analysis was used to adjust transfusion of FFP, platelets, and PRBCs for known MOF risk factors.

The results showed that among all the patients, 346 (24%) developed MOF, and 118 (8.2%) died. The analysis detected a significant interaction between units of FFP and PRBCs transfused; but regardless of the units of PRBCs transfused, FFP transfusion was independently associated with the development of MOF; but the deleterious effect associated with FFP transfusion was found to be more prominent among patients receiving fewer than 6 units of PRBCs. Platelet transfusion was unassociated with MOF after adjustment for age, ISS, and FFP, and PRBC transfusion. The researchers recommended that further work was needed to develop clotting assays that differentiate between types of coagulopathy, and that the study highlights the need for improved transfusion protocols. The study was published in the October 2010 issue of Archives of Surgery.

"The scientific rationale for early fresh frozen plasma administration remains a matter of debate; neither the efficacy nor the safety of this approach is well described,” said lead author Jeffrey Johnson, M.D. and colleagues of the department of surgery. "In fact, the clinical efficacy of FFP transfusion remains largely unproven, and most evidence for FFP administration is from observational data alone.”

FFP refers to the fluid portion of one unit of human blood that has been centrifuged, separated, and frozen solid at -18 °C or colder within eight hours of collection. It contains the labile as well as stable components of the coagulation, fibrinolytic, and complement systems; the proteins that maintain oncotic pressure and modulate immunity; and other proteins that have diverse activities. In addition, fats, carbohydrates, and minerals are present in concentrations similar to those in circulation. There is little scientific evidence to support the increasing use of FFP in clinical medicine purely for volume expansion; while FFP is a reliable solution for intravascular volume replacement in acute blood loss, alternative therapies are equally satisfactory and considerably safer.

Related Links:

University of Colorado



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.